Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

NAVELBINE SOFT CAPSULE 20 MG [SIN12546P]

Active ingredients: NAVELBINE SOFT CAPSULE 20 MG

View product's general information
Last updated 24 April 2026

Product Info

NAVELBINE SOFT CAPSULE 20 MG

[SIN12546P]

Product information

Active Ingredient and Strength

VINORELBINE - 20 MG

Dosage Form

CAPSULE, LIQUID FILLED

Manufacturer and Country

FAREVA PAU 1 (PRIMARY/SECONDARY PACKAGER) - FRANCE
CATALENT GERMANY EBERBACH GMBH - GERMANY

Registration Number

SIN12546P

Licence Holder

PIERRE FABRE SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

L01CA04

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 – Therapeutic indications
Non-small cell lung cancer – Advanced Breast Cancer

Dosing

4.2 – Posology and method of administration
Navelbine® soft capsules must be given strictly by the oral route.
Navelbine® soft capsules should be swallowed with water without chewing or sucking the capsule. It is recommended to take the capsule with some food.

• As a single agent: The recommended regimen is:
First three administrations
60 mg/m2 of body surface area, administered once weekly.
Subsequent administrations
Beyond the third administration, it is recommended to increase the dose of Navelbine® to 80 mg/m2 once weekly except in those patients for whom the neutrophil count dropped once below 500/mm3 or more than once between 500 and 1000/mm3 during the first three administrations at 60 mg/m2.

Navelbine Soft Capsule Dosage Table 1



• Dose Modification
For any administration planned to be given at 80 mg/m2, if the neutrophil count is below 500/mm3, the administration should be delayed until recovery and the dose reduced from 80 to 60 mg/m2 per week during the 3 following administrations.

Navelbine Soft Capsule Dosage Table 2



It is possible to re-escalate the dose from 60 to 80 mg/m2 per week if the neutrophil count did not drop below 500/mm3 or more than once between 500 and 1000/mm3 during 3 administrations given at 60 mg/m2 according to the rules previously defined for the first 3 administrations.

• For combination regimens, the dose and schedule will be adapted to the treatment protocol
Based on clinical studies, the oral dose of 80 mg/m2 was demonstrated to correspond to 30 mg/m2 of the IV form and 60 mg/m2 to 25 mg/m2.
This has been the base for combination regimens alternating IV and oral forms improving patient’s convenience.
For combination regimens, the dose and schedule will be adapted to the treatment protocol. The following table gives the dose required for appropriate ranges of body surface area (BSA).

Navelbine Soft Capsule Dosage Table 3



Table caption

Even for patients with BSA ≥ 2 m2 the total dose should never exceed 120 mg per week at 60 mg/m2 and 160 mg per week at 80 mg/m2.

Administration in the elderly
Clinical experience has not detected any significant differences among elderly patients with regards to response rate, although greater sensitivity in some of these patients cannot be excluded. Age does not modify the pharmacokinetics of vinoreline (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Administration in children
Safety and efficacy in children have not been established and administration is therefore not recommended (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Administration in patients with liver insufficiency
Navelbine® can be administered at the standard dose of 60 mg/m2/week in patients with mild liver impairment (bilirubin < 1.5 x ULN, and ALAT and/or ASAT from 1.5 to 2.5 x ULN). In patients with moderate liver impairment (bilirubin from 1.5 to 3 x ULN, whatever the levels of ALAT and ASAT), Navelbine® should be administered at a dose of 50 mg/m2/week. The administration of Navelbine® in patients with severe hepatic impairment is not recommended as there is insufficient data to determine the pharmacokinetics, efficacy and safety of Navelbine® in this population (see sections 4.3, 4.4, 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Administration in patients with renal insufficiency
Given the minor renal excretion, there is no pharmacokinetic justification for reducing the dose of Navelbine® in patients with serious renal insufficiency (see sections 4.4, 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Instructions for use and / handling of oral Navelbine® (see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Contraindications

4.3 – Contra-indications

  • Known hypersensitivity to vinorelbine or other vinca alkaloids or to any of the constituent.

  • Disease significantly affecting absorption.

  • Previous significant surgical resection of stomach or small bowel.

  • Neutrophil count < 1500/mm3 or severe infection current or recent (within 2 weeks).

  • Platelet count < 100000/mm3.

  • Patients requiring long-term oxygen therapy.

  • Lactation (see section 4.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

  • In combination with yellow fever vaccine (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).